Equitable Trust’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.2M | Sell |
20,829
-581
| -3% | -$33.4K | 0.05% | 222 |
|
|
2026
Q1 | $1.3M | Buy |
21,410
+672
| +3% | +$39.2K | 0.06% | 196 |
|
|
2025
Q4 | $1.12M | Hold |
20,738
| – | – | 0.05% | 218 |
|
|
2025
Q3 | $935K | Sell |
20,738
-175
| -0.8% | -$8.17K | 0.04% | 240 |
|
|
2025
Q2 | $968K | Sell |
20,913
-177
| -0.8% | -$8.69K | 0.05% | 231 |
|
|
2025
Q1 | $1.29M | Hold |
21,090
| – | – | 0.07% | 190 |
|
|
2024
Q4 | $1.19M | Sell |
21,090
-800
| -4% | -$44.7K | 0.07% | 198 |
|
|
2024
Q3 | $1.13M | Sell |
21,890
-2,166
| -9% | -$102K | 0.07% | 192 |
|
|
2024
Q2 | $999K | Buy |
24,056
+355
| +1% | +$15.9K | 0.07% | 196 |
|
|
2024
Q1 | $1.29M | Sell |
23,701
-6,520
| -22% | -$332K | 0.09% | 162 |
|
|
2023
Q4 | $1.55M | Sell |
30,221
-607
| -2% | -$31.9K | 0.12% | 138 |
|
|
2023
Q3 | $1.79M | Sell |
30,828
-1,175
| -4% | -$72K | 0.15% | 123 |
|
|
2023
Q2 | $2.05M | Hold |
32,003
| – | – | 0.16% | 120 |
|
|
2023
Q1 | $2.22M | Sell |
32,003
-1,953
| -6% | -$138K | 0.17% | 110 |
|
|
2022
Q4 | $2.44M | Sell |
33,956
-3,308
| -9% | -$249K | 0.19% | 108 |
|
|
2022
Q3 | $2.65M | Buy |
37,264
+1,400
| +4% | +$102K | 0.22% | 97 |
|
|
2022
Q2 | $2.76M | Buy |
35,864
+200
| +0.6% | +$15.2K | 0.21% | 99 |
|
|
2022
Q1 | $2.6M | Buy |
35,664
+3,343
| +10% | +$224K | 0.17% | 119 |
|
|
2021
Q4 | $2.02M | Buy |
32,321
+400
| +1% | +$23.5K | 0.12% | 142 |
|
|
2021
Q3 | $1.89M | Sell |
31,921
-1,224
| -4% | -$80.6K | 0.12% | 138 |
|
|
2021
Q2 | $2.21M | Sell |
33,145
-4,725
| -12% | -$308K | 0.14% | 127 |
|
|
2021
Q1 | $2.39M | Buy |
37,870
+881
| +2% | +$54.8K | 0.18% | 120 |
|
|
2020
Q4 | $2.29M | Buy |
36,989
+1,048
| +3% | +$64.4K | 0.17% | 121 |
|
|
2020
Q3 | $2.17M | Sell |
35,941
-378
| -1% | -$22.8K | 0.18% | 115 |
|
|
2020
Q2 | $2.14M | Buy |
36,319
+1,216
| +3% | +$72.7K | 0.2% | 106 |
|
|
2020
Q1 | $1.96M | Buy |
35,103
+2,800
| +9% | +$171K | 0.22% | 109 |
|
|
2019
Q4 | $2.07M | Sell |
32,303
-2,248
| -7% | -$129K | 0.2% | 103 |
|
|
2019
Q3 | $1.75M | Sell |
34,551
-1,755
| -5% | -$82.5K | 0.18% | 113 |
|
|
2019
Q2 | $1.65M | Sell |
36,306
-909
| -2% | -$42.3K | 0.17% | 114 |
|
|
2019
Q1 | $1.77M | Buy |
37,215
+559
| +2% | +$27.8K | 0.21% | 107 |
|
|
2018
Q4 | $1.91M | Sell |
36,656
-2,085
| -5% | -$112K | 0.25% | 100 |
|
|
2018
Q3 | $2.4M | Sell |
38,741
-315
| -0.8% | -$18.7K | 0.28% | 98 |
|
|
2018
Q2 | $2.16M | Buy |
+39,056
| New | +$2.11M | 0.27% | 104 |
|
Other funds holding BMY
AIM
FWIA
DLA
Equitable Trust's BMY Position: Q2 2026 in Review
Equitable Trust reduced its Bristol-Myers Squibb (BMY) stake by 2.7% in Q2 2026, selling an estimated $33.4K and leaving 20,829 shares worth $1.2M. The position accounts for 0.05% of the portfolio, ranked #222.
Equitable Trust first reported a position in BMY in Q2 2018 and has held it in 33 quarters since. The position peaked at $2.76M in Q2 2022. 889 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Equitable Trust held 20,829 shares of Bristol-Myers Squibb worth $1.2M as of Q2 2026.
- Equitable Trust sold 581 Bristol-Myers Squibb shares in Q2 2026, an estimated $33.4K.
- Bristol-Myers Squibb made up 0.05% of Equitable Trust's portfolio in Q2 2026, its #222 holding.
- Equitable Trust first reported a position in Bristol-Myers Squibb in Q2 2018 and has held it in 33 quarters since.
- Equitable Trust's Bristol-Myers Squibb position peaked at $2.76M in Q2 2022.
- 889 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Equitable Trust's 13F filing for Q2 2026, filed 23 Jul 2026.